The researchers highlighted a need for the detection of more relevant markers and guidance on how to treat adverse events (AEs), the types and severity of which vary based on disease type.
Amidst growing uptake of programmed cell death protein 1/programmed cell death protein ligand 1 (PD‐1/PD‐L1) treatment for a variety of cancers, researchers are putting a spotlight on the need for better recognition of immune-related adverse events (irAEs) to facilitate early detection, diagnosis, and intervention.
Their findings appear in a recent issue of International Journal of Oncology.
Across the board, management of irAEs typically includes symptomatic treatment with or without the discontinuation of PD‐1/PD‐L1 treatment, according to the researchers. The group did add, however, that there is currently “no perfect system” for recognizing and diagnosing the AEs in a timely manner, leaving providers to adopt a “discovery-symptom treatment” strategy. As a result of, they wrote, there is a need for the detection of more relevant markers and guidance on how to treat events, the types and severity of which vary based on disease type.
“As the number of PD‐1/PD‐L1–related inhibitors developed increases, a growing number of patients with cancer will benefit from them. However, unfortunately this also means there will be an increase in the number of irAEs, and this danger should be taken into consideration when administering these drugs and patients should be carefully monitored throughout the treatment course and even after treatment is discontinued,” flagged the researchers.
In one clinical trial of patients receiving treatment with PD‐1/PD‐L1 inhibitors, reports of treatment-related AEs had a calculated probability of 77%, with 29% of patients experiencing more serious AEs.
In their paper, the researchers compiled common management strategies associated with PD‐1/PD‐L1 inhibitors, including of the neuromuscular, respiratory, circulatory, digestive, and endocrine systems, as well as ocular complications, joint damage, and granulomatous venereal disease.
“According to the reported statistics on adverse reactions, skin lesions including pruritus, psoriasis, and nodular dermatitis account for 46% to 62% of reports, autoimmune colitis accounted for 22% to 48% of reports, autoimmune hepatitis accounted for 7% to 33% of reports, and endocrine diseases such as thyroiditis, hypophysitis, adrenalitis, and diabetes account for 12% to 34% of reports,” detailed the researchers. “In addition, there were other rarer adverse reactions, including pneumonia (3%‐8%), nephritis (1%‐7%), cardiac adverse reactions including myocarditis (5%), and neurological adverse reactions (1%‐5%).”
In many cases, further testing is needed when a patient shows symptoms of an irAE, and in general, once confirmed, irAEs are treated with targeted therapy that includes hormone therapy, such as corticosteroids.
For example, when a patient shows symptoms of lower leg swelling, muscle pain, or precordial pain after receiving PD‐1/PD‐L1 treatment, electrocardiograms are recommended to confirm if the patient is experiencing a circulatory system-related irAE. If confirmed, patients should be treated with symptomatic treatment that can include hormones and implantation of a pacemaker.
Further testing is also recommended in patients experiencing diarrhea, frequent urination, or severe bladder pain in order to determine if the symptoms are urinary-related irAEs. If an irAE is confirmed, treatment primarily comprises oral hormone treatment.
Similar methods are taken for speculation of respiratory-related AEs that, if confirmed, are then often treated with corticosteroids and targeted anti-inflammatory and antibacterial drugs. Corticosteroids, as well as topical hormone therapy, are also commonly used in the case of skin lesions—the most common irAE associated with PD‐1/PD‐L1 treatment.
Although rare, hematologic-related irAEs have also been reported with PD‐1/PD‐L1 treatment, and these are primarily addressed with hormone therapy.
Reference
Sun G, Liu H, Shi X, et al. Treatment of patients with cancer using PD-1/PD-L1 antibodies: adverse events and management strategies. Int J Oncol. Published online April 28, 2022. doi:10.3892/ijo.2022.5364
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Study Highlights BMP7 As a Potential Therapeutic Target for Ovarian Cancer
November 30th 2023High Bone Morphogenetic Protein 7 (BMP7) expression was significantly associated with aggressive phenotypes, including advanced grade, International Federation of Gynecology and Obstetrics stage, residual disease, and adverse overall survival.
Read More
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More